Partnering

Pharmacyclics could get $975 million in PCI-32765 license deal

Posted on 09 December 2011

Tags: , , , ,

Janssen Biotech has executed an agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765.

A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

Interim data were reported at the 2011 American Society of Clinical Oncology Annual Meeting and oral presentations on two separate Phase 2 studies will be presented at the upcoming American Society of Hematology Meeting in December, along with several other poster presentations.

"The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies," said William N. Hait, M.D., Ph.D., Global Therapeutic Head, Oncology, for Janssen. "PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies."

According to the terms of the agreement, the companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities.

Janssen has made an upfront payment of $150 million which will be recorded in the fourth quarter, and will make additional payments based upon the achievement of certain development and regulatory milestones.

Related items:

Read the Point of view article

Purchase the Partnering Agreements with Johnson & Johnson report

View the 2011 Partnering Scorecard

View the full deal record at Current Partnering (subscription required)

Read the story at Bloomberg

Print Friendly, PDF & Email

Leave a Reply